Clinical Trials Browser

Phase 1/2 × Has results × olaparib × Clear all

NCT02734004 2026-04-20

MEDIOLA

Phase 1/2 Active not recruiting

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT01116648 2026-03-05

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Phase 1/2 Active not recruiting

155 enrolled 34 charts

BreastGynecologic

Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms

NCT03008278 2026-02-03

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

Phase 1/2 Completed

51 enrolled 20 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT04972110 2025-10-30

ATTACC

Phase 1/2 Terminated

156 enrolled 19 charts

Other solid neoplasm

Advanced Solid Tumor, Adult

NCT02769962 2025-07-28

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

Phase 1/2 Completed

45 enrolled 30 charts

GenitourinaryThoracic

Carcinoma, Transitional Cell, Lung Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT05405309 2025-06-03

CORONADO CLL

Phase 1/2 Terminated

5 enrolled 13 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04556617 2025-04-08

PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 1/2 Terminated

19 enrolled 11 charts

Adenocarcinoma, Prostatic Neoplasms

NCT01513174 2024-06-28

GOAL

Phase 1/2 Completed

186 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung